inclusion criteria: 1. male and female \> 18 and \< 80 years of age. 2. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. 3. patient hospitalized due to covid-19 in the last 24 hours. 4. hospitalized patients meeting the criteria for moderate covid-19, as set forth by the may 2020 fda guidance for industry: covid-19: developing drugs and biological products for treatment or prevention, patients with symptoms of moderate illness with covid-19, which could include any symptom of mild illness (such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea) or shortness of breath with exertion with at least one of the following clinical signs: 1. respiratory rate: ≥ 20 breaths/minute; 2. spo2: \> 93% on room air at sea level; 3. heart rate: ≥ 90 beats/minute; 5. signed written informed consent by the patient. 6. women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrolment .

inclusion criteria: 1. male and female \> 18 and \< 80 years of age. 2. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. 3. patient hospitalized due to covid-19 in the last 24 hours. 4. hospitalized patients meeting the criteria for moderate covid-19, as set forth by the may 2020 fda guidance for industry: covid-19: developing drugs and biological products for treatment or prevention, patients with symptoms of moderate illness with covid-19, which could include any symptom of mild illness (such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea) or shortness of breath with exertion with at least one of the following clinical signs: 1. respiratory rate: ≥ 20 breaths/minute; 2. spo2: \> 93% on room air at sea level; 3. heart rate: ≥ 90 beats/minute; 5. signed written informed consent by the patient. 6. women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrolment .

inclusion criteria: male and female > 18 and < 80 years of age. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. patient hospitalized due to covid-19 in the last 24 hours. hospitalized patients meeting the criteria for moderate covid-19, as set forth by the may 2020 fda guidance for industry: covid-19: developing drugs and biological products for treatment or prevention, patients with symptoms of moderate illness with covid-19, which could include any symptom of mild illness (such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea) or shortness of breath with exertion with at least one of the following clinical signs: respiratory rate: ≥ 20 breaths/minute; spo2: > 93% on room air at sea level; heart rate: ≥ 90 beats/minute; signed written informed consent by the patient. women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrolment .

inclusion criteria: male and female > 18 and < 80 years of age. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. patient hospitalized due to covid-19 in the last 24 hours. hospitalized patients meeting the criteria for moderate covid-19, as set forth by the may 2020 fda guidance for industry: covid-19: developing drugs and biological products for treatment or prevention, patients with symptoms of moderate illness with covid-19, which could include any symptom of mild illness (such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea) or shortness of breath with exertion with at least one of the following clinical signs: respiratory rate: ≥ 20 breaths/minute; spo2: > 93% on room air at sea level; heart rate: ≥ 90 beats/minute; signed written informed consent by the patient. women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrolment .

inclusion criteria: 1. male and female > 18 and < 80 years of age. 2. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. 3. patient hospitalized due to covid-19 in the last 24 hours. 4. hospitalized patients meeting the criteria for moderate covid-19, as set forth by the may 2020 fda guidance for industry: covid-19: developing drugs and biological products for treatment or prevention, patients with symptoms of moderate illness with covid-19, which could include any symptom of mild illness (such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea) or shortness of breath with exertion with at least one of the following clinical signs: 1. respiratory rate: ≥ 20 breaths/minute; 2. spo2: > 93% on room air at sea level; 3. heart rate: ≥ 90 beats/minute; 5. signed written informed consent by the patient. 6. women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrolment .

inclusion criteria: 1. male and female > 18 and < 80 years of age. 2. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. 3. patient hospitalized due to covid-19 in the last 24 hours. 4. hospitalized patients meeting the criteria for moderate covid-19, as set forth by the may 2020 fda guidance for industry: covid-19: developing drugs and biological products for treatment or prevention, patients with symptoms of moderate illness with covid-19, which could include any symptom of mild illness (such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea) or shortness of breath with exertion with at least one of the following clinical signs: 1. respiratory rate: ≥ 20 breaths/minute; 2. spo2: > 93% on room air at sea level; 3. heart rate: ≥ 90 beats/minute; 5. signed written informed consent by the patient. 6. women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrolment .

inclusion criteria: 1. male and female > 18 and < 80 years of age. 2. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. 3. patients classified according to nih severity classification as: critical illness: individuals who have respiratory failure, and/or septic shock, and/or multiple organ dysfunction 4. signed written informed consent by the patient. 5. women and men who are of childbearing potential, willing to use acceptable contraceptive measures for the entire study duration.

inclusion criteria: 1. male and female > 18 and < 80 years of age. 2. laboratory confirmation of sars-cov-2 infection by rt-pcr from any diagnostic sampling source. 3. patients classified according to nih severity classification as: critical illness: individuals who have respiratory failure, and/or septic shock, and/or multiple organ dysfunction 4. signed written informed consent by the patient. 5. women and men who are of childbearing potential, willing to use acceptable contraceptive measures for the entire study duration.